Improving Cervical Cancer Screening Among the LGBT Community

Article

January is National Cervical Cancer Awareness Month, and until now, it has been a challenge for many in the lesbian, gay, bisexual, and transgender (LGBT) community to receive proper screening for various reasons.

The cure rate for cervical cancer is relatively high, but many women are still dying from the disease due to lack of screening and the ramped-up spread of HPV. This statistic may be even higher for women within the LGBT population.

Many LGBT individuals and their families face many barriers when it comes to healthcare and cancer prevention. The disparity and the risk exist for many reasons:

  • The ban on same-sex marriage in many states prevents individuals from obtaining health insurance through their partners.
  • Workplace discrimination causes people to be terminated and left with no health insurance.
  • Some healthcare professionals discriminate on the basis of the patient's sexual orientation.
  • Physicians and/or lesbians may not recognize the risk of contracting HPV from female partners.
  • STD information is not discussed enough within the LGBT community. Lesbians have higher prevalence of smoking and obesity.
  • Poor mental health due to continuing discrimination may deter many of these women from being screened.

Unfortunately, lesbians and bisexual women are 10 times less likely than heterosexual women to be screened for cervical cancer. But with the implementation of the Affordable Care Act (ACA), many women will be able to receive annual Pap smears, along with ongoing education.

The ACA will ensure that these women receive the necessary medical care so that:

  • Many LGBT individuals and their families have equal access to coverage.
  • Marketplaces use education, outreach, and enrollment strategies that are culturally competent and relevant for the LGBT community.
  • Marketplaces collect confidential demographic information about sexual orientation and gender identity and use it to serve the LGBT community better.

Do you find that the LGBT community is underserved when it comes to cancer prevention and screening? What has your facility done to make an impact?

References:

Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Related Content